Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.

ABSTRACT:

Background

Data on mepolizumab in patients with severe eosinophilic asthma (EA) and comorbidities are needed to assess whether randomized controlled trial results are applicable in the real world.

Objective

To evaluate real-life effectiveness and the presence/absence of predictors of treatment response in patients with one or more comorbidities (nasal polyps, allergic rhinitis, gastro-esophageal reflux disease, nonallergic rhinitis with eosinophilia syndrome, obesity, bronchiectasis) who received mepolizumab (MEPO) for the treatment of severe EA.

Methods

We performed a single-center retrospective study in patients with severe asthma and presence of comorbidities treated with mepolizumab at the respiratory outpatient clinic, Policlinico-Vittorio Emanuele, Catania, Ital

SUBMITTER: Crimi C 

PROVIDER: S-EPMC7508691 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature